Zydus Acquires Assertio Holdings for $166.4 Million

In a significant move within the pharmaceutical sector, Zydus Worldwide DMCC, a subsidiary of India-based Zydus Lifesciences, has finalized an agreement to acquire Assertio Holdings for approximately $166.4 million in an all-cash transaction. This acquisition marks a strategic expansion for Zydus, aiming to bolster its presence in key therapeutic areas.

The deal values each outstanding share of Assertio common stock at $23.50. This valuation represents a substantial premium, notably exceeding previous offers. Specifically, it stands at a 30.6% increase over an earlier proposed transaction with Garda Therapeutics announced in April 2026, and a 7.8% uplift from a revised Garda agreement from May 2026. The offer also reflects a compelling 75.8% premium compared to Assertio's stock price prior to March 20, 2026, underscoring the attractive terms presented by Zydus.

Assertio's board of directors unanimously determined that the proposal from Zydus constituted a "Superior Proposal" under its existing merger agreement with Garda Therapeutics. Consequently, the company authorized the termination of the prior agreement to pursue the more advantageous offer from Zydus. This decision was informed by a thorough evaluation of critical factors including the offer's pricing, the certainty of execution, the financing structure, and the overall terms of the transaction.

A key element that distinguished the Zydus offer was its robust financing structure. The agreement is entirely cash-funded, with no reliance on third-party financing or any financing contingencies. This assurance of immediate and complete funding, fully guaranteed by a Zydus entity, provided the board with significant confidence in the deal's successful completion. This contrasts with many acquisition scenarios that can face hurdles related to financing arrangements.

The acquisition process will commence with Zydus Worldwide DMCC initiating a tender offer to acquire all publicly held shares of Assertio. Following the successful completion of the tender offer, any remaining shares not acquired will be absorbed through a subsequent merger, all at the agreed-upon price of $23.50 per share. Upon closing, Assertio's shares will cease trading on the Nasdaq exchange, transitioning into a privately held entity under Zydus's ownership.

Industry analysts view this acquisition as a strategic play by Zydus Lifesciences to enhance its product portfolio and market reach, particularly within the U.S. pharmaceutical market. The specialty pharmaceutical sector, where Assertio operates, has seen increased M&A activity as larger players seek to acquire niche products and established patient bases. The transaction is anticipated to conclude in the second quarter of 2026, contingent upon standard closing conditions, including the tender of a majority of Assertio's shares. Notably, no significant regulatory approvals are anticipated for this deal, streamlining the path to completion.

Moelis & Company served as the financial advisor to Assertio Holdings, with Gibson, Dunn & Crutcher providing legal counsel. Longacre Square Partners advised on strategy and communications. Heather Mason, Chair Of The Board Of Directors at Assertio Holdings, commented, \"We are pleased that the comprehensive and disciplined strategic review process undertaken by the Board has yielded this outcome. After carefully evaluating all relevant factors, including price, certainty of value, execution risk and overall transaction terms, the Board determined that the Zydus offer represents the best path available to Assertio shareholders.\"